Buy & Sell General Dynamics Corporation (GD) – General Dynamics Corporation Price Today
Aura AI Summary
Key Stats
- $92.73BMarket Cap
- IndustrialsSector
- -14.64%3M Drawdown
- $98.91BEnterprise Value
- 1.78%Dividend Yield
- 100% Buy | 0% SellTrading Activity
- 74 daysTypical Hold Time
General Dynamics Corporation (GD) is currently valued at a market capitalization of $92.73B, with an enterprise value of $98.91B. Over the past 52 weeks, General Dynamics Corporation has traded between a low of $273.64 and a high of $368.69, highlighting its annual price range. Over the past three months, General Dynamics Corporation has recorded a drawdown of -14.64%, reflecting recent price volatility. General Dynamics Corporation offers a dividend yield of 1.78%, with the most recent dividend of $1.59 paid on 10 Apr 26. On average, investors hold General Dynamics Corporation for approximately 74 days, indicating typical investor behavior on the platform.
About General Dynamics Corporation
General Dynamics is a defense contractor and business jet manufacturer. The firm's segments include aerospace, combat systems, marine, and technologies. The company's aerospace segment creates Gulfstream business jets. Combat system produces land-based combat vehicles, such as the M1 Abrams tank. The marine subsegment creates nuclear-powered submarines, among other things. The technologies segment contains two main units, an IT business that primarily serves the government market and a mission systems business that focuses on products that provide command, control, computers, intelligence, surveillance, and reconnaissance capabilities to the military.
Most Recent News
Enhanced Games debuts in Las Vegas with boosted athletes and a TikTok-friendly sports format
Enhanced Games will hold its first competition in Las Vegas featuring 50 enhanced athletes, including Olympic and world champions, competing in a new sports format designed for digital and social media viewing. The event combines track, pool, and wei...

Phibro Animal Health CEO sold 21,120 shares worth $1.2 million
Phibro Animal Health's CEO recently sold 21,120 shares of the company, generating proceeds of approximately $1.2 million. This insider sale might indicate the CEO's personal financial planning or a strategic move, but it could also raise questions am...

Patient Square buys 210,000 shares of Nektar Pharmaceuticals, signaling strong confidence.
Patient Square has purchased 210,000 shares of Nektar Pharmaceuticals (NKTR), indicating a significant investment move. This purchase reflects Patient Square's confidence in Nektar's future prospects and potential growth. Investors may view this as a...
